Oxadiazole inhibitors of leukotriene production

Disclosed are 1,2,4-oxadiazoles of formula (I): or pharmaceutically acceptable salts thereof, for example; 5-(4-{ 2-[5-(5-methoxypyridin-3-yl)-1,2,4-oxadiazol-3-yl]-3-methylbutan-2-yl} phenyl)pyrimidin-2-amine. The invention also relates to pharmaceutical compositions comprising these compounds, pro...

Full description

Saved in:
Bibliographic Details
Main Authors Loke Pui Leng, De Lombaert Stephane, Morwick Tina Marie, Lo Ho Yin, Liu Weimin, Bartolozzi Alessandra, Chen Zhidong, Bosanac Todd, Huber John D, Olague Alan, Zindell Renee, Wu Lifen, Riether Doris, Tye Heather
Format Patent
LanguageEnglish
Published 27.06.2014
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:Disclosed are 1,2,4-oxadiazoles of formula (I): or pharmaceutically acceptable salts thereof, for example; 5-(4-{ 2-[5-(5-methoxypyridin-3-yl)-1,2,4-oxadiazol-3-yl]-3-methylbutan-2-yl} phenyl)pyrimidin-2-amine. The invention also relates to pharmaceutical compositions comprising these compounds, processes for preparing these compounds and intermediates useful in these processes. The compounds are intended for use in the treatment of leukotriene-mediated disorders including cardiovascular, inflammatory, allergic, pulmonary and fibrotic diseases, renal diseases and cancer.
Bibliography:Application Number: NZ20110605690